Open Access<p>Development of an Orally Bioavailable Isoliquiritigenin Self-Nanoemulsifying Drug Delivery System to Effectively Treat Ovalbumin-Induced Asthma</p>
Author(s) -
Mingzhuo Cao,
Mengling Zhan,
Zheng Wang,
Zeqian Wang,
Xiumin Li,
Mingsan Miao
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s269982
Subject(s) - bioavailability , zeta potential , pharmacology , drug delivery , medicine , in vivo , pharmacokinetics , ovalbumin , chemistry , materials science , immunology , nanotechnology , nanoparticle , organic chemistry , microbiology and biotechnology , immune system , biology
Isoliquiritigenin (ILQ), an important component of Anti-Asthma Herbal Medicine Intervention (ASHMI), had shown potent anti-asthma effect in vitro in our previous study. However, poor solubility and low bioavailability hindered in vivo application to treat asthma. This study was to develop a novel ILQ loaded self-nanoemulsifying drug delivery system (ILQ-SMEDDS) with enhanced bioavailability.